INS and type 2 diabetes mellitus: As shown in Figure 3, metformin represented the highest usage rate by the T2DM patients (86%), then sulfonylureas (glibenclamide, gliclazide, glimepiride, and glipizide) and insulin (both sulfonylureas and insulin groups were used by 55% of the patients).